Genomics England
Charterhouse Square, London, Greater London, EC1M 6BQ, United Kingdom
Overview
Genomics England is a wholly owned company of the Department of Health set up to deliver the 100,000 Genomes Project. It was made possible by the National Institute for Health Research, NHS England, Public Health England, and Health Education England. Genomics England sequences 100,000 whole genomes from NHS patients and their families. Its four main aims include bringing benefit to patients, creating an ethical and transparent program based on consent, supporting new scientific discovery and medical insights, and kick-starting the development of the U.K. genomics industry. Genomics England is focusing on patients with rare diseases, and their families, as well as patients with common cancers. It was announced by Jeremy Hunt, Secretary of State for Health, as part of the NHS 65th birthday celebrations in 2013. It is based in London, England.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Genetics
- Health Care
Investment portfolio
- Seven Bridges
Led · Grant · Mar 2015
Seven Bridges provides the Seven Bridges Platform, a scalable, cloud-based suite of tools for biomedical and genomic data analysis used in cancer research, drug development and precision medicine. The platform supports multi- and hybrid-cloud deployments (Google Cloud, Amazon Web Services and other public and private clouds) and enables reproducible, collaborative analysis of large genomic datasets. Thousands of researchers and major projects—including the U.S. National Cancer Institute’s Cancer Genomics Cloud pilot and Genomics England’s 100,000 Genomes Project—use the platform, and Seven Bridges is the NIH’s only commercial Trusted Partner for access to large cancer genomics datasets. The company said the new funding will support ongoing innovation of the platform and help it continue to support users at the NCI, NIH, Genomics England and pharmaceutical partners. Seven Bridges recently made its platform available on Google Cloud to enable easier choice of computing infrastructure and reproducible analyses. The company has offices in Cambridge, Mass.; Belgrade; London; and San Francisco. Seven Bridges Genomics develops a Graph Genome reference and a suite of bioinformatics tools for storing and analyzing large sets of human genomes. Its Graph Genome includes a self-improving algorithm and can anonymize patient genetic data while retaining information needed for research and interpretation. The company is launching related tools including a graph aligner, branch genotyper and local assembler, a graph database, a genome browser, and disease-focused applications. All of these tools are designed to run on the Seven Bridges Platform, a cloud-based bioinformatics, computation and storage suite. Led by CEO Deniz Kural, the company intends to use newly awarded funds to complete and launch the functional Graph Genome reference and its suite of tools.
Team
No current team members are available.